Nutriband vs China SXT Pharmaceuticals
Nutriband is the larger business, with $2.0m of revenue in fiscal 2026 against $1.1m for China SXT Pharmaceuticals (1.8 times as much). Nutriband grew faster (-4.8% against -34.6%). Nutriband kept more of each dollar of sales as profit: a net margin of -404.1% against -545.2%. Nutriband carries less debt relative to equity (0.5% against 3.4%).
| Latest fiscal year | NutribandNTRB, 2026 | China SXT PharmaceuticalsSXTC, 2026 |
|---|---|---|
| Revenue | $2.0m | $1.1m |
| Revenue growth | -4.8% | -34.6% |
| Net income | −$8.2m | −$6.2m |
| Operating margin | -408.4% | -625.9% |
| Net margin | -404.1% | -545.2% |
| Return on equity | -125.6% | -27.5% |
| Free cash flow | −$5.1m | −$4.0m |
| Cash | $4.6m | $28.2m |
| Total debt | $35,861 | $999,565 |
| Debt to equity | 0.5% | 3.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 500 | — |
| Market value | $76.8m | $2.0m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |